Nachman Norwood & Parrott’s AstraZeneca AZN Stock Holding History

Nachman Norwood & Parrott’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	$905K	Buy	7,554 +46	+0.6%	+$5.05K	0.09%	138
2021 Q1	$746K	Buy	7,508 +434	+6%	+$43.6K	0.08%	149
2020 Q4	$707K	Hold	7,074	–	–	0.08%	144
2020 Q3	$775K	Sell	7,074 -24	-0.3%	-$2.67K	0.1%	124
2020 Q2	$751K	Sell	7,098 -12	-0.2%	-$1.24K	0.12%	122
2020 Q1	$635K	Buy	7,110 +26	+0.4%	+$2.45K	0.13%	119
2019 Q4	$706K	Hold	7,084	–	–	0.12%	135
2019 Q3	$631K	Hold	7,084	–	–	0.11%	137
2019 Q2	$585K	Sell	7,084 -43	-0.6%	-$3.37K	0.11%	139
2019 Q1	$576K	Hold	7,127	–	–	0.11%	135
2018 Q4	$541K	Buy	+7,127	New	+$557K	0.11%	131

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Nachman Norwood & Parrott's AZN Position: Q2 2021 in Review

Nachman Norwood & Parrott increased its AstraZeneca (AZN) stake by 0.61% in Q2 2021, buying an estimated $5.05K and bringing the position to 7,554 shares worth $905K. The position accounts for 0.09% of the portfolio, ranked #138.

Nachman Norwood & Parrott first reported a position in AZN in Q4 2018 and has held it in 11 quarters since. 769 funds tracked by Wall St. Rank hold AZN as of Q2 2021.

Nachman Norwood & Parrott held 7,554 shares of AstraZeneca worth $905K as of Q2 2021.
Nachman Norwood & Parrott bought 46 AstraZeneca shares in Q2 2021, an estimated $5.05K.
AstraZeneca made up 0.09% of Nachman Norwood & Parrott's portfolio in Q2 2021, its #138 holding.
Nachman Norwood & Parrott first reported a position in AstraZeneca in Q4 2018 and has held it in 11 quarters since.
769 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2021.

Based on Nachman Norwood & Parrott's 13F filing for Q2 2021, filed 13 Aug 2021.